Generic Name and Formulations:
Dimenhydrinate 50mg; scored tabs.
McNeil Consumer Healthcare
Indications for DRAMAMINE:
Motion sickness prophylaxis.
50–100mg every 4–6 hours, starting ½–1 hour before travel; max 400mg/day.
<2 years: not recommended. 2–6 years: 12.5–25mg; max 75mg/day. 6–11 yrs: 25–50mg; max 150mg/day. Both: starting ½–1 hour before travel; may repeat every 6–8 hours.
Asthma or chronic respiratory disease. Glaucoma. Arrhythmias. GI or urinary obstruction. Phenylketonuria (chewable tabs). Pregnancy (Cat.B). Nursing mothers: not recommended.
Potentiates CNS depression with alcohol, other CNS depressants. May potentiate ototoxicity of antibiotics (esp. aminoglycosides).
Drowsiness, sedation, anticholinergic effects, paradoxical excitement in children.
Tabs—12, 36, 100
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC